Nabriva Therapeutics AG (NBRV) Forecasted to Post FY2016 Earnings of ($1.38) Per Share
Nabriva Therapeutics AG (NASDAQ:NBRV) – Equities research analysts at Wedbush upped their FY2016 earnings estimates for Nabriva Therapeutics AG in a report issued on Wednesday. Wedbush analyst H. Behanna now expects that the firm will post earnings per share of ($1.38) for the year, up from their previous estimate of ($1.47). Wedbush currently has a “Outperform” rating and a $17.00 target price on the stock. Wedbush also issued estimates for Nabriva Therapeutics AG’s Q4 2016 earnings at ($0.16) EPS, Q1 2017 earnings at ($0.16) EPS, Q2 2017 earnings at ($0.16) EPS, Q3 2017 earnings at ($0.16) EPS, FY2017 earnings at ($0.53) EPS, FY2018 earnings at ($0.35) EPS, FY2019 earnings at ($0.39) EPS and FY2020 earnings at ($0.37) EPS.
A number of other brokerages have also recently issued reports on NBRV. HC Wainwright began coverage on shares of Nabriva Therapeutics AG in a report on Thursday, September 8th. They issued a “buy” rating and a $16.00 price objective for the company. Zacks Investment Research upgraded shares of Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $8.50 price objective for the company in a report on Friday, August 12th. Finally, Leerink Swann reiterated an “outperform” rating and issued a $14.00 price objective on shares of Nabriva Therapeutics AG in a report on Thursday, October 27th. Five investment analysts have rated the stock with a buy rating, Nabriva Therapeutics AG currently has an average rating of “Buy” and a consensus price target of $13.15.
Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) opened at 4.25 on Friday. The company’s market capitalization is $90.49 million. The company has a 50-day moving average price of $5.88 and a 200 day moving average price of $7.29. Nabriva Therapeutics AG has a one year low of $3.52 and a one year high of $10.69.
A number of large investors have recently added to or reduced their stakes in NBRV. Jackson Park Capital LLC purchased a new stake in Nabriva Therapeutics AG during the second quarter worth about $195,000. Opaleye Management Inc. raised its position in shares of Nabriva Therapeutics AG by 24.5% in the first quarter. Opaleye Management Inc. now owns 273,800 shares of the company’s stock worth $2,453,000 after buying an additional 53,800 shares in the last quarter. Finally, Baker BROS. Advisors LP bought a new position in shares of Nabriva Therapeutics AG during the third quarter worth approximately $2,468,000. Institutional investors own 63.05% of the company’s stock.
Nabriva Therapeutics AG Company Profile
Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs).
Receive News & Stock Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related stocks with our FREE daily email newsletter.